MedElevator
Войти в исследования Frontiers in neurology · 2026
Case Report: Isolated homonymous hemianopia after reversal of anticoagulation with andexanet alfa.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Malekahmadi Paria, Abdelsalam Dina, Ibrahim Safa, Lee Andrew Go
Аннотация
PURPOSE: Clinical scoring systems have been developed (e.g., CHA2DS2-VASc and HAS-BLED) to aid in the perioperative management of anticoagulation therapy. The decision to continue, modify, or stop anticoagulation prior to surgical procedures requires multidisciplinary input and an individualised plan. Decisions both to continue or reverse anticoagulation can cause visual loss.
OBSERVATIONS: We report the use of andexanet alfa (recombinant inactive factor Xa) as a reversal agent for anticoagulation in atrial fibrillation after surgical bleeding, which resulted in secondary homonymous hemianopsia and ischemic infarct.
CONCLUSION AND IMPORTANCE: Stroke is a major risk factor for atrial fibrillation, and anticoagulation in specific settings is evidence-based. Anticoagulation, however, increases the risk of haemorrhage and may require the use of a reversal agent (e.g., Andexanet alfa) in cases of severe bleeding. Unfortunately, reversal of anticoagulation in this setting can lead to an ischemic stroke and visual loss.
OBSERVATIONS: We report the use of andexanet alfa (recombinant inactive factor Xa) as a reversal agent for anticoagulation in atrial fibrillation after surgical bleeding, which resulted in secondary homonymous hemianopsia and ischemic infarct.
CONCLUSION AND IMPORTANCE: Stroke is a major risk factor for atrial fibrillation, and anticoagulation in specific settings is evidence-based. Anticoagulation, however, increases the risk of haemorrhage and may require the use of a reversal agent (e.g., Andexanet alfa) in cases of severe bleeding. Unfortunately, reversal of anticoagulation in this setting can lead to an ischemic stroke and visual loss.